Bristol-Myers Squibb (BMY) Stock News

Bristol Myers Squibb (NYSE:BMY) and Pfizer have announced a significant direct-to-patient program for their anticoagulant medication Eliquis® (apixaban). Starting September 8, 2025, eligible U.S. patients can purchase Eliquis directly through the Eliquis 360 Support program at a 40% discount from the current list price.

The program will provide direct shipping across all 50 states and Puerto Rico, offering simplified access and cost transparency. With over 15 million Americans prescribed Eliquis since launch, the medication has generated an estimated $3 billion in healthcare cost savings per 100,000 patients treated through reduced hospitalizations and rehabilitation needs.

Bristol Myers Squibb (NYSE: BMY) announced FDA approval of significant label updates for its CAR T cell therapies Breyanzi and Abecma. The updates include reduced patient monitoring requirements and removal of REMS programs, reflecting increased confidence in the therapies' safety profiles.

Key changes include reduction of driving restrictions from 8 to 2 weeks and requirement to stay near healthcare facilities reduced from 4 to 2 weeks post-treatment. Currently, only 2 in 10 eligible patients receive cell therapy treatment due to logistical and geographic barriers.

BMS will work with over 150 treatment centers to implement these changes and expand into community cancer centers nationwide, aiming to increase accessibility to these potentially life-saving treatments.

Bristol Myers Squibb (NYSE: BMY) has declared its latest quarterly dividend payments. The company will pay a quarterly dividend of $0.62 per share on its common stock, payable on August 1, 2025, to stockholders of record as of July 3, 2025. Additionally, BMY announced a quarterly dividend of $0.50 per share on its $2.00 convertible preferred stock, which will be paid on September 2, 2025, to stockholders of record as of August 5, 2025. This dividend announcement reflects BMY's commitment to providing regular returns to its shareholders.

Bristol Myers Squibb announced groundbreaking results from the TRANSCEND FL trial's marginal zone lymphoma cohort evaluating Breyanzi (lisocabtagene maraleucel). The study showed remarkable efficacy with 95.5% overall response rate and 62.1% complete response rate in relapsed/refractory MZL patients. At 24 months, 88.6% maintained response duration, with 85.7% progression-free survival and 90.4% overall survival. Safety profile remained consistent, with manageable cytokine release syndrome (76% any grade, 4% Grade 3) and neurologic events (33% any grade, 4% Grade 3). This marks Breyanzi's success in a fifth cancer type, the most among CD19-directed CAR T therapies. The therapy demonstrated particular promise for MZL patients, who typically face a 3-5 year median survival after multiple relapses.

Bristol Myers Squibb (NYSE: BMY) presented promising data from its targeted protein degradation platform at EHA 2025, featuring clinical findings on CELMoD agents and BCL6 ligand-directed degrader. Key highlights include mezigdomide showing 75-85% overall response rates in multiple myeloma, iberdomide demonstrating 88.9% response rate in newly diagnosed multiple myeloma, and golcadomide achieving up to 94% response rate in follicular lymphoma when combined with rituximab. The first-in-human study of BCL6 LDD (BMS-986458) showed an 81% overall response rate in non-Hodgkin lymphoma. Multiple Phase 3 trials are ongoing with data readouts expected between 2025-2030. The company's protein degraders are designed to target specific disease-driving proteins and potentially enhance existing therapies' efficacy.

Bristol Myers Squibb (NYSE: BMY) has scheduled its second quarter 2025 financial results announcement for Thursday, July 31, 2025. The company will host a conference call and live webcast at 8:00 a.m. ET, where executives will discuss the quarterly performance with the investment community. Investors and the public can access the webcast at investor.bms.com, where related materials will be available before the call. A replay will be accessible approximately three hours after the call concludes at the same website.

Bristol Myers Squibb (BMY) announced positive Phase 3 POETYK PsA-1 trial results for Sotyktu in adults with psoriatic arthritis. The trial met its primary endpoint with 54.2% of Sotyktu-treated patients achieving ACR20 response versus 34.1% for placebo at Week 16 (p<0.0001). The drug showed significant improvements across multiple measures including joint symptoms, skin conditions, and quality of life. Key secondary endpoints were met, including PASI 75 response and other clinical measures. New data from POETYK PsA-2 trial demonstrated maintained efficacy through Week 52, with 62.2% of continuous Sotyktu patients achieving ACR20 response. The safety profile remained consistent with previous trials, with upper respiratory tract infection being the most common adverse event (5.1% vs 3.0% for placebo).

Bristol Myers Squibb (NYSE: BMY) has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference scheduled for June 11, 2025. The company will engage in a fireside chat starting at 10:00 a.m. ET. Both investors and the general public can access the session through the company's investor relations website at http://investor.bms.com. An archived recording of the session will be made available after its conclusion.

Bristol Myers Squibb (NYSE: BMY) has received European Commission approval for Opdivo SC, a new subcutaneous formulation of its PD-1 inhibitor nivolumab, across multiple solid tumor indications. This marks Opdivo as the first and only PD-1 inhibitor approved for subcutaneous use in the EU. The approval is based on the Phase 3 CheckMate -67T trial, which demonstrated noninferiority in pharmacokinetics and consistent efficacy compared to the intravenous formulation. The new formulation reduces administration time to just 3-5 minutes, compared to traditional IV infusion. The approval covers use as monotherapy, maintenance therapy following IV nivolumab plus Yervoy combination, or in combination with chemotherapy or cabozantinib. The safety profile remained consistent with the IV formulation, with serious adverse reactions occurring in 28% of patients.